When cooled below their LCST during cryosurgery, the cold-responsive nanoparticles rapidly release the encapsulated therapeutic agents to induce ICD and downregulate PD-L1 expression in breast cancer cells. This evidence concerns the gene CD274 and breast carcinoma.